Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Up Big Yet Again Today

By George Budwell – Jun 5, 2020 at 8:57AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax scores another large grant for its COVID-19 vaccine candidate.

What happened

Shares of the developmental-stage vaccine company Novavax (NVAX -6.42%) are gearing up for another strong session today. In premarket action Friday morning, the biotech's shares jumped by as much as 14.2%.

The spark? Novavax announced after the closing bell Thursday that the U.S. Department of Defense (DoD) had awarded the company a handsome $60 million to fund the manufacturing of its experimental COVID-19 vaccine, NVX‑CoV2373. As part of the deal, Novavax will reportedly deliver 10 million doses of NVX-CoV2373 to the DoD later this year.

A businessman drawing a positive trending curve with his index finger. 2020 sits at the apex of the curve.

Image source: Getty Images.

So what

Novavax was surprisingly left off President Trump's list of the five COVID-19 vaccine developers with the best chance of success. The big deal is that the five companies that did make the list will all reportedly receive federal funds and logistical support for their clinical trials. With the DoD's financial support, though, Novavax should have a much better chance of competing with these other vaccine developers favored by the administration.  

Now what

Novavax kicked off an early-stage trial for NVX‑CoV2373 late last month -- making it one of the first companies to actually enter the clinic with a COVID-19 vaccine candidate. If things go as planned, the biotech should have preliminary data by next month. These initial data, in turn, will form the basis of the biotech's next steps for NVX‑CoV2373. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$21.00 (-6.42%) $-1.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.